Baxter International Stock Plummets 0.93% on Tuesday
June 24, 2023
🌥️Trending News
On Tuesday, Baxter International ($NYSE:BAX) Inc. stock proved to be an outlier in an otherwise grim trading session, underperforming its competitors with shares dropping 0.93% to $44.94. This continues a downward trend in Baxter’s valuation, as it has steadily declined since the start of the year. Baxter International Inc. is a publicly traded American health care company that specializes in renal therapy and medication delivery systems, as well as medical products for critical care and surgery. The company has a diverse portfolio of products, with its most profitable divisions being cardiovascular and general medicine.
Its mission is to save and sustain lives by providing innovative products and services that advance patient care. Baxter International Inc. is traded on the New York Stock Exchange under the ticker symbol BAX.
Analysis
At GoodWhale, we can help you analyze BAXTER INTERNATIONAL’s financials. Our Risk Rating analysis of the company indicates that it is a high risk investment from a financial and business perspective. Upon further investigation of their balance sheet, cashflow statement, and non financial statements, we have identified three risk warnings. If you register with us, you can get access to these warning indicators. With our help, you can make an informed and well-thought-out decision about BAXTER INTERNATIONAL’s financials. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Baxter International. More…
| Total Revenues | Net Income | Net Margin |
| 15.05k | -2.46k | -4.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Baxter International. More…
| Operations | Investing | Financing |
| 1.48k | -797 | -1.26k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Baxter International. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 28.29k | 22.35k | 11.62 |
Key Ratios Snapshot
Some of the financial key ratios for Baxter International are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 9.3% | 2.0% | -12.8% |
| FCF Margin | ROE | ROA |
| 5.1% | -20.5% | -4.2% |
Peers
Baxter International Inc is a large medical device company. Its main competitors are Utah Medical Products Inc, Clarity Medical Group Holding Ltd, and Merit Medical Systems Inc.
– Utah Medical Products Inc ($NASDAQ:UTMD)
The company’s market cap is $313.74 million and its ROE is 11.43%. Utah Medical Products, Inc. engages in the design, manufacture, and marketing of medical devices. It operates through the following segments: Pregnancy & Newborn, Patient Care, and Animal Health. The Pregnancy & Newborn segment offers a line of products used by obstetricians, gynecologists, and neonatal caregivers for the health and well-being of pregnant women and their babies. The Patient Care segment provides a line of products used by hospitals, clinics, and home healthcare providers for the treatment of respiratory and other conditions. The Animal Health segment offers a line of products used by veterinarians for the health and well-being of animals.
– Clarity Medical Group Holding Ltd ($SEHK:01406)
According to Clarity Medical Group Holding Ltd’s market cap as of 2022, the company is worth 599.47 million. Clarity Medical Group Holding Ltd is a Medical Group that provides healthcare services. The company was founded in 2014 and is headquartered in Hong Kong.
– Merit Medical Systems Inc ($NASDAQ:MMSI)
Medstronic is a medical device company that manufactures and sells a variety of medical devices and equipment. The company has a market cap of 3.29B as of 2022 and a ROE of 5.86%. Medtronic’s products are used in a variety of medical procedures, including cardiac surgery, vascular surgery, and neurology.
Summary
Baxter International Inc., a medical device manufacturing company, saw its stock price fall 0.93% to $44.94 on Tuesday, underperforming the broad market which was down overall. This was driven by investors selling off the company’s shares, indicating a lack of confidence in the company’s potential and outlook. Analysts suggest that a combination of weak earnings forecasts and political uncertainty are factors contributing to Baxter’s stock underperforming. Investors should keep a close watch on the company’s performance and any news that could affect its stock price in the near future.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
